Investors / United States / Samsara BioCapital
Samsara BioCapital
Venture capital · Palo Alto, CA, United States · North America
Samsara BioCapital is a life sciences investment firm that partners with biotech companies. It describes a collaborative and patient-capital philosophy and brings together scientists, physicians, drug developers and business leaders to back therapeutic breakthroughs.
Invests inHealthcare & Biotech
In its own wordsbiotechtherapeuticslife sciencesdrug developmenthealthcare
Your fit with Samsara BioCapital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsSamsara BioCapital lists 36 checked portfolio companies on its own site and is named in 13 funding rounds, 3 of them as lead. Its most frequent entry is Series B, 62% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 89% of its companies are based in United States. It invests most often alongside RA Capital, Vivo Capital and ARCH Venture Partners.
Counts come from funding rounds that name Samsara BioCapital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Samsara BioCapital's whole history. Rounds on record name 13 companies; its own site lists 36. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundSamsara BioCapital does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 23% |
| Series B | 62% |
| Growth | 15% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 4 | 2 |
| '26 | 9 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 73th | 35 companies |
| Recent activity | 95th | 11 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 80th | 11% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 70th | 4 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 9 |
| Vivo Capital | 5 |
| ARCH Venture Partners | 4 |
| Altamont Pharmaceutical Holdings | 4 |
| Casdin Capital | 4 |
| Nextech Invest | 4 |
| Pivotal Life Sciences | 4 |
| Sofinnova | 4 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers36100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Samsara BioCapital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Samsara BioCapital| Date | Company | Stage |
|---|---|---|
| 5 Nov 2026 | Series B | |
| 28 Jul 2026 | Series B Led | |
| 22 Jun 2026 | Series B | |
| 28 Apr 2026 | Series A | |
| 31 Mar 2026 | Series B | |
| 26 Jan 2026 | Series B | |
| 8 Jan 2026 | Series C+ | |
| 8 Jan 2026 | Series B |
Round details for Samsara BioCapital
Amounts, full round histories and every co-investor in Samsara BioCapital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
36 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alpha-9 Oncology is a clinical stage radiopharmaceutical company advancing a portfolio of molecules to treat cancer cells | Healthcare & Biotech | Portfolio page | ||
| Alpheus Medical is developing a new drug-ultrasound therapy for glioblastoma. | Healthcare & Biotech | May 2025Series B | Page + round | |
| Alumis Inc is focused on immune-mediated disease therapies | Healthcare & Biotech | Portfolio page | ||
| Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders. | Healthcare & Biotech | Mar 2026Series B | Funding round | |
| Autobahn Therapeutics creates the next generation of regenerative medicines for the brain to improve life health for people affected by CNS disorders | Healthcare & Biotech | Portfolio page | ||
| Bolt Biotherapeutics develops treatments for cancer | Healthcare & Biotech | Portfolio page | ||
| Claris Bio is developing therapies for sight-threatening conditions, including limbal stem cell deficiency | Healthcare & Biotech | Jul 2026Series B | Funding round | |
| Contineum Therapeutics is pioneering new therapies for conditions at the intersection of inflammatory and fibrotic diseases. | Healthcare & Biotech | Portfolio page | ||
| Apr 2026Series A | Funding round | |||
| EpiBiologics develops medicines that use bispecific antibodies to selectively degrade disease-causing extracellular proteins | Healthcare & Biotech | Jan 2026Series B | Page + round | |
| Exo Therapeutics develops breakthrough medicines by modulating enzyme activity in oncology and inflammation with precision and potency | Healthcare & Biotech | Portfolio page | ||
| Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development of its investigational drug product, seralutinib, for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). | Healthcare & Biotech | Portfolio page | ||
| Inventiva is a clinical-stage biotechnology company developing an oral treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). | Healthcare & Biotech | Portfolio page | ||
| IO Biotech develops therapeutic cancer vaccines | Healthcare & Biotech | Portfolio page | ||
| LENZ Therapeutics is a pharmaceutical company focused on the commercialization of an eye drop for the treatment of presbyopia | Healthcare & Biotech | Portfolio page | ||
| Link Cell Therapies is a biotechnology company that develops next-generation CAR-T therapeutics for solid and hematologic cancers | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| Mineralys Therapeutics is focused on improving outcomes for people managing hypertension, CKD and related diseases driven by dysregulated aldosterone. | Healthcare & Biotech | Portfolio page | ||
| The company is a privately held, late clinical-stage biopharmaceutical company. | Healthcare & Biotech | Portfolio page | ||
| Neurogene develops life-changing genetic medicines for people and their families impacted by devastating neurological diseases. | Healthcare & Biotech | Portfolio page | ||
| Nkarta Inc. is dedicated to realizing the potential of natural killer cells for the treatment of autoimmune diseases. | Healthcare & Biotech | Portfolio page |
About this data
site last read 11 Nov 2026- Site
- samsaracap.com
- Last read
- 11 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 15 May 2025
- Companies checked
- 36
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Samsara BioCapital's profile as data
Pull Samsara BioCapital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/samsaracap.com
# also
GET /v1/firms/samsaracap.com/portfolio
GET /v1/firms/samsaracap.com/coinvestors
GET /v1/firms/samsaracap.com/news